The biotechnology company Aspect Biosystems has successfully closed a Series B financing round and raised 115 million US dollars. The round was led by Dimension, an investment firm specializing in technology and life sciences. Other investors, including Novo Nordisk, Radical Ventures and the T1D Fund, also participated. The fresh capital will be used to drive the development of bioprinted tissue therapeutics and support the growth of the company’s platform technology.
Aspect Biosystems specializes in the biotechnological production of functional tissues. These approaches are expected to enable a new category of cell therapies and regenerative treatments for complex metabolic and endocrine diseases such as diabetes. The company plans to use the funds from the financing round to transfer several programs into clinical development. At the same time, the proprietary platform, which combines AI-supported bioprinting technology, computer-aided design, therapeutic cells and advanced biomaterials, will be further expanded.
“I am incredibly proud of the progress our team is making on our mission to develop disease-modifying treatments for people living with serious diseases,” said Tamer Mohamed, Founder and CEO, Aspect Biosystems. “We are thrilled to partner with Dimension and this exceptional, mission-aligned investor syndicate. We are grateful for their support as we embark on our next chapter dedicated to transforming patient outcomes for the better.”
Another milestone for Aspect Biosystems was the appointment of Nan Li, Founder and Managing Partner of Dimension, to the company’s Board of Directors.
“Aspect is an embodiment of the multi-disciplinary companies that we believe will define the next chapter of biotech,” said Nan Li, Founder & Managing Partner, Dimension. “The company brings together capabilities across tissue engineering, cell therapy, biomaterials, computer vision and robotics to deliver on the promise of regenerative medicine. We are beyond excited to partner with the Aspect team to advance their programs forward and to build a generational company.”
In addition to the funding round, Aspect Biosystems recently announced a $200 million partnership with the governments of Canada and British Columbia and a collaboration with Novo Nordisk. These initiatives underscore the company’s commitment to developing innovative approaches for the treatment of diabetes and obesity.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
